M. Levy (Middlesex, United Kingdom), J. Wedzicha (London, United Kingdom)
Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD
B. Celli, A. Emmett, G. Crater, C. Kalberg (Boston, Research Triangle Park, United States Of America)
|   |
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo
J. B. Soriano, D. D. Sin, X. Zhang, J. A. Anderson, N. R. Anthonisen, A. S. Buist, P. S. Burge, P. M. Calverley, H. Muellerova, D. S. Postma, J. Vestbo (Spain; Canada; United Kingdom; USA; Netherlands)
| |
Tiotropium reduces the risk of COPD exacerbation irrespective of its characterization by the treatment intervention
D. M. G. Halpin, S. Menjoge, K. Viel (Exeter, United Kingdom; Ridgefield, United States Of America; Ingelheim, Germany)
| |
Adherence to national guidelines on antibiotic prescription for COPD
R. A. Heinink, T. J. Fletcher (Sutton Coldfield, Birmingham, United Kingdom)
| |
The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients
M. Moretti, R. Assereto (Modena, Milan, Italy)
| |
Lung volume response to bronchodilators is dependent on the stage of the disease in chronic obstructive pulmonary disease (COPD) patients
P. W. Boros, M. Franczuk, S. Wesolowski (Warsaw, Poland)
| |
Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
T. E. Delea, M. Hagiwara, M. Akazawa, R. Stanford (Brookline, Research Triangle Park, United States Of America)
| |
Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids
Y. Shanshal, R. L. Sharrock (Gateshead, United Kingdom)
| |